The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,007
Neutrophil perversion in demyelinating autoimmune diseases: Mechanisms to medicine
Casserly, C. S., Nantes, J. C., Hawkins, R. W., & Vallières, L. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.01.013 · Cited by 52
Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012
Burkill, S. M., Montgomery, S., Hajiebrahimi, M., Hillert, J. A., Olsson, T. P., & Bahmanyar, S. (2017) · Neurology · doi:10.1212/wnl.0000000000004216 · Cited by 52
Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis
Poddighe, S., Murgia, F., Lorefice, L., Liggi, S., Cocco, E. E., Marrosu, M. G., & Atzori, L. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.07.004 · Cited by 53
Sguassero, A., Artiga, Á., Morasso, C., Jiménez, R. R., Martín‐Rapún, R., Mancuso, R., Agostini, S., Hernis, A., Ābols, A., Linē, A., et al. (2018) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-018-1331-0 · Cited by 52
Nazareth, T. A., Rava, A. R., Polyakov, J. L., Banfe, E. N., Waltrip, R. W., Zerkowski, K., & Herbert, L. B. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.09.002 · Cited by 52
Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis
Lipp, I., Jones, D. K., Bells, S., Sgarlata, E., Foster, C., Stickland, R., Davidson, A. E., Tallantyre, E. C., Robertson, N. P., Wise, R. G., et al. (2019) · Human Brain Mapping · doi:10.1002/hbm.24568 · Cited by 54
Zhang, Y., Taylor, B. V., Simpson, S., Blizzard, L., Campbell, J. A., Palmer, A. J., & van der Mei, I. A. F. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520958369 · Cited by 56
Lassiter, G., Melancon, C., Rooney, T., Murat, A.-M., Kaye, J. S., Kaye, A. M., Kaye, R. J., Cornett, E. M., Kaye, A. D., Shah, R. J., et al. (2020) · Neurology International · doi:10.3390/neurolint12030016 · Cited by 52
Potential Role of CHI3L1+ Astrocytes in Progression in MS
Cubas-Núñez, L., Gil‐Perotín, S., Castillo-Villalba, J., López, V. P., Tarazona, L. R. S., Gasqué-Rubio, R., Carratalà‐Boscà, S., Alcalà-Vicente, C., Miralles, F. C. P., Lassmann, H., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000972 · Cited by 58
Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study
Patti, F., Chisari, C. G., Arena, S., Toscano, S., Finocchiaro, C., Fermo, S. L., Judica, M. L., & Maimone, D. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103361 · Cited by 55
Cree, B., Arnold, D. L., Fox, R. J., Gold, R., Vermersch, P., Benedict, R. H. B., Bar‐Or, A., Piani-Meier, D., Rouyrre, N., Ritter, S., et al. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585221083194 · Cited by 51
Self-citationEstimation of migraine prevalence considering active and inactive states across different age groups
Piccininni, M., Brinks, R., Rohmann, J. L., & Kurth, T. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01624-y · Cited by 51
Klotz, L., Smolders, J., Lehto, J., Matilainen, M., Lütje, L., Buchholz, L., Albrecht, S., Walter, C., Varghese, J., Wiendl, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03625-7 · Cited by 51
Raphael, I., Webb, J., Stüve, O., Haskins, W. E., & Forsthuber, T. G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.991315 · Cited by 51
Self-citationSaposnik, G., Sempere, Á. P., Raptis, R., Prefasi, D., Selchen, D. H., & Mauriño, J. (2016) · BMC Neurology · doi:10.1186/s12883-016-0577-4 · Cited by 53
Neuroimaging Techniques to Assess Inflammation in Multiple Sclerosis
Tommasin, S., Giannì, C., Giglio, L. D., & Pantano, P. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.07.055 · Cited by 51
The MSBase registry: Informing clinical practice
Kalinčík, T., & Butzkueven, H. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519848965 · Cited by 53
A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis
Wentling, M., Gomez, C. L., Park, H.-J., Amatruda, M., Ntranos, A., Aramini, J. M., Petracca, M., Rusielewicz, T., Chen, E., Tolstikov, V., et al. (2019) · Brain · doi:10.1093/brain/awz201 · Cited by 51
Self-citationMitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients
Biasi, S. D., Simone, A. M., Bianchini, E., Tartaro, D. L., Pecorini, S., Nasi, M., Patergnani, S., Carnevale, G., Gibellini, L., Ferraro, D., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201948223 · Cited by 51
Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations.
Robertson, D. S., & Moreo, N. (2016) · Europe PMC (PubMed Central) · Cited by 50
Relevance of Autophagy and Mitophagy Dynamics and Markers in Neurodegenerative Diseases
Giorgi, C., Bouhamida, E., Danese, A., Previati, M., Pinton, P., & Patergnani, S. (2021) · Biomedicines · doi:10.3390/biomedicines9020149 · Cited by 51
Sodium MRI of multiple sclerosis
Petracca, M., Fleysher, L., Oesingmann, N., & Inglese, M. (2015) · NMR in Biomedicine · doi:10.1002/nbm.3289 · Cited by 50
Self-citationFraussen, J., Bock, L., & Somers, V. A. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.008 · Cited by 50
Kantorová, E., Poláček, H., Bittšanský, M., Baranovičová, E., Hnilicová, P., Čierný, D., Sivák, Š., Nosáľ, V., Zeleňák, K., & Kurča, E. (2017) · Neurological Research · doi:10.1080/01616412.2016.1275460 · Cited by 50
Progressive Forms of Multiple Sclerosis
Zeydan, B., & Kantarci, O. H. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.08.006 · Cited by 52
Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis
Wu, Q., Mills, E. A., Wang, Q., Dowling, C. A., Fisher, C., Kirch, B., Lundy, S. K., Fox, D. A., Mao‐Draayer, Y., & the AMS04 Study Group (2020) · JCI Insight · doi:10.1172/jci.insight.134251 · Cited by 50
Bsteh, G., Hegen, H., Altmann, P., Auer, M., Berek, K., Pauli, F. D., Wurth, S., Zinganell, A., Rommer, P. S., Deisenhammer, F., et al. (2020) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217320966344 · Cited by 52
Neuropathic Pain in Neurologic Disorders: A Narrative Review
Mitsikostas, D. D., Μoka, Ε., Orrillo, E., Aurilio, C., Vadalouca, A., Paladini, A., & Varrassi, G. (2022) · Cureus · doi:10.7759/cureus.22419 · Cited by 53
González‐Lorenzo, M., Ridley, B., Minozzi, S., Giovane, C. D., Peryer, G., Piggott, T., Foschi, M., Filippini, G., Tramacere, I., Baldin, E., et al. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011381.pub3 · Cited by 53
Singh, J., Deshpande, M., Suhail, H., Rattan, R., & Giri, S. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9630-0 · Cited by 50
Severe, Highly Active, or Aggressive Multiple Sclerosis
Freedman, M. S., & Rush, C. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000331 · Cited by 49
Self-citationJongen, P. J., Stavrakaki, I., Voet, B., Hoogervorst, E. L. J., van Munster, E., Linssen, W. H. J. P., Sinnige, L. G. F., Verhagen, W. I. M., Visser, L. H., van der Kruijk, R., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8183-3 · Cited by 49
Acute Multiple Sclerosis Relapse
Berkovich, R. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000330 · Cited by 49
Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
Alroughani, R., Akhtar, S., Ahmed, S. F., Behbehani, R. S., & Al-Hashel, J. Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165846 · Cited by 52
Drugs approved for the treatment of multiple sclerosis: review of their safety profile
Auricchio, F., Scavone, C., Cimmaruta, D., di Mauro, G., Capuano, A., Sportiello, L., & Rafaniello, C. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1388371 · Cited by 53
Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge
Zettl, U. K., Hecker, M., Aktaş, O., Wagner, T. B., & Rommer, P. S. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1426462 · Cited by 49
Recovery of cognitive function after relapse in multiple sclerosis
Benedict, R. H. B., Pol, J., Yasin, F., Hojnacki, D. W., Kolb, C., Eckert, S. P., Tacca, B., Drake, A. S., Wojcik, C. M., Morrow, S. A., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519898108 · Cited by 49
Amoruso, A., Blonda, M., Gironi, M., Grasso, R., Di Francescantonio, V., Scaroni, F., Furlan, R., Verderio, C., & Avolio, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-63282-3 · Cited by 46
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis
Villoslada, P., & Steinman, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757647 · Cited by 49
Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis
Coronado, I., Gabr, R. E., & Narayana, P. A. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520921364 · Cited by 49
Long-term prognostic value of longitudinal measurements of blood neurofilament levels
Häring, D. A., Kropshofer, H., Kappos, L., Cohen, J. A., Shah, A. H., Meinert, R., Leppert, D., Tomic, D., & Kühle, J. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000856 · Cited by 49
Self-citationMacrophages and Autoantibodies in Demyelinating Diseases
Koike, H., & Katsuno, M. (2021) · Cells · doi:10.3390/cells10040844 · Cited by 49
Soundy, A., Roskell, C., Elder, T., Collett, J., & Dawes, H. (2016) · Open Journal of Therapy and Rehabilitation · doi:10.4236/ojtr.2016.41003 · Cited by 48
Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications
Wang, X., Liang, Z., Wang, S., Ma, D., Zhu, M., & Feng, J. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210629145351 · Cited by 49
Rehabilitation treatment of multiple sclerosis
Duan, H., Jing, Y., Li, Y., Lian, Y., Li, J., & Li, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168821 · Cited by 48
AI-driven reclassification of multiple sclerosis progression
Ganjgahi, H., Häring, D. A., Aarden, P., Graham, G., Sun, Y., Gardiner, S., Su, W. W., Berge, C., Bischof, A., Fisher, E., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03901-6 · Cited by 49
Self-citationSurvey of diagnostic and treatment practices for multiple sclerosis in Europe
Fernández, Ó., Delvecchio, M., Edan, G., Fredrikson, S., Gionvannoni, G., Hartung, H., Havrdová, E., Kappos, L., Pozzilli, C., Soerensen, P. S., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13236 · Cited by 48
Self-citationIdentity Concealment and Chronic Illness: A Strategic Choice
Cook, J., Salter, A. R., & Stadler, G. (2017) · Journal of Social Issues · doi:10.1111/josi.12221 · Cited by 52
Social Cognition Abilities in Patients With Different Multiple Sclerosis Subtypes
Henry, A., Tourbah, A., Chaunu, M., Bakchine, S., & Montreuil, M. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617717000510 · Cited by 51
Dynamics and heterogeneity of brain damage in multiple sclerosis
Kotelnikova, E. A., Kiani, N. A., Abad, E. M., Martínez‐Lapiscina, E. H., Andorrà, M., Zubizarreta, I., Valdeolivas, I. P., Pertsovskaya, I., Alexopoulos, L. G., Olsson, T. P., et al. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005757 · Cited by 50
Multiple Sclerosis Identification Based on Fractional Fourier Entropy and a Modified Jaya Algorithm
Wang, S., Cheng, H., Phillips, P., & Zhang, Y. (2018) · Entropy · doi:10.3390/e20040254 · Cited by 48
Hudgens, S. A., Schüler, R., Stokes, J., Eremenco, S., Hunsche, E., & Leist, T. P. (2019) · Value in Health · doi:10.1016/j.jval.2018.11.007 · Cited by 48
Ribeiro, C. M., Oliveira, S. R., Alfieri, D. F., Flauzino, T., Kaimen-Maciel, D. R., Simão, A. N. C., Maes, M. H. J., & Reiche, E. M. V. (2019) · Inflammation Research · doi:10.1007/s00011-019-01286-0 · Cited by 51
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View
Maglione, A., Rolla, S., Mercanti, S. F. D., Cutrupi, S., & Clerico, M. (2019) · Cells · doi:10.3390/cells8101280 · Cited by 48
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
Fernández-Diaz, E. M., Pérez-Vicente, J. A., Villaverde, R., Ruiz, L. B., Candeliere-Merlicco, A., Martínez-Navarro, M. L., Gil, J. G., Sánchez, C., Alfaro, A., Diaz, I., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51282 · Cited by 49
Baharlooi, H., Nouraei, Z., Azimi, M., Moghadasi, A. N., Tavassolifar, M. J., Moradi, B., Sahraian, M. A., & Izad, M. H. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.13013 · Cited by 50
Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches
Jafari, A., Babajani, A., & Rezaei–Tavirani, M. (2021) · Biomarker Insights · doi:10.1177/11772719211013352 · Cited by 48
Hecker, M., Bühring, J., Fitzner, B., Rommer, P. S., & Zettl, U. K. (2021) · Biomolecules · doi:10.3390/biom11101510 · Cited by 49
Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
Negron, A., Stüve, O., & Forsthuber, T. G. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.607766 · Cited by 47
Self-citationA significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study
Westerlind, H., Stawiarz, L., Fink, K., Hillert, J. A., & Manouchehrinia, A. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516643394 · Cited by 47
Prosperini, L., & Pontecorvo, S. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s85099 · Cited by 47
Aluminium in Brain Tissue in Multiple Sclerosis
Mold, M. J., Chmielecka, A., Rodriguez, M. R. R., Thom, F., Linhart, C., King, A., & Exley, C. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15081777 · Cited by 47
Ziemssen, T., Piani-Meier, D., Bennett, B., Johnson, C., Tinsley, K., Trigg, A., Hach, T., Dahlke, F., Tomic, D., Tolley, C., et al. (2020) · Journal of Medical Internet Research · doi:10.2196/16932 · Cited by 47
Self-citationCiampi, E., Uribe-San-Martín, R., Cárcamo, C., Cruz, J. P., Reyes, A., Reyes, D., Pinto, C., Vásquez, M., Burgos, R. A., & Hancke, J. L. (2020) · BMC Neurology · doi:10.1186/s12883-020-01745-w · Cited by 47
Morgan, B. P., Gommerman, J. L., & Ramaglia, V. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.600656 · Cited by 51
Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
Berger, A. A., Sottosanti, E., Winnick, A. A., Izygon, J. J., Berardino, K., Cornett, E. M., Kaye, A. D., Varrassi, G., Viswanath, O., & Urits, I. (2021) · Neurology International · doi:10.3390/neurolint13020022 · Cited by 48
Development of an age‐adjusted model for blood neurofilament light chain
Harp, C. T., Thanei, G., Jia, X., Kühle, J., Leppert, D., Schaedelin, S. A., Benkert, P., von Büdingen, H., Hendricks, R., & Herman, A. H. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51524 · Cited by 52
Personalized Medicine in Multiple Sclerosis
Giovannoni, G. (2017) · Neurodegenerative Disease Management · doi:10.2217/nmt-2017-0035 · Cited by 46
Treatment adherence and transitioning youth in pediatric multiple sclerosis
Lulu, S., Julian, L. J., Shapiro, E. M., Hudson, K., & Waubant, E. L. (2014) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2014.09.088 · Cited by 46
Self-citationvan Kempen, Z. L. E., Leurs, C. E., Lissenberg-Witte, B. I., de Vries, A., Wattjes, M. P., Rispens, T., & Killestein, J. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517708464 · Cited by 46
Moccia, M., Capacchione, A., Lanzillo, R., Carbone, F., Micillo, T., Perna, F., Rosa, A. D., Carotenuto, A., Albero, R., Matarese, G., et al. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418819074 · Cited by 46
Galluzzo, P., Capri, F. C., Vecchioni, L., Realmuto, S., Scalisi, L., Cottone, S., Nuzzo, D., & Alduina, R. (2021) · Life · doi:10.3390/life11070620 · Cited by 46
Correale, J. D., Halfón, M. J., Jack, D. L., Rubstein, A., & Villa, A. M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103264 · Cited by 48
Geladaris, A., Torke, S., & Weber, M. S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00951-z · Cited by 45
Li, E., Zheng, Y., Cai, M., Lai, Q., Fang, G., Du, B., Shen, C., Zhang, Y., Wu, L., & Ding, M. (2022) · Epilepsia · doi:10.1111/epi.17315 · Cited by 45
Identification and management of subclinical disease activity in early multiple sclerosis: a review
Ontaneda, D., Chitnis, T., Rammohan, K. W., & Obeidat, A. Z. (2023) · Journal of Neurology · doi:10.1007/s00415-023-12021-5 · Cited by 47
Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients
Cavallari, M., Palotai, M., Glanz, B. I., Egorova, S., Prieto, J. C., Healy, B. C., Chitnis, T., & Guttmann, C. R. G. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516635874 · Cited by 45
Leurs, C. E., Podlesniy, P., Trullás, R., Balk, L. J., Steenwijk, M. D., Malekzadeh, A., Piehl, F., Uitdehaag, B. M. J., Killestein, J., van Horssen, J., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517699874 · Cited by 45
Santis, S. D., Granberg, T., Ouellette, R., Treaba, C. A., Herranz, E., Fan, Q., Mainero, C., & Toschi, N. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101699 · Cited by 45
Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study
Maxwell, K. F., Bhattacharya, S., Bodziak, M. L., Jakimovski, D., Hagemeier, J., Browne, R. W., Weinstock‐Guttman, B., Zivadinov, R., & Ramanathan, M. K. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089664 · Cited by 45
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS
Cellerino, M., Cordano, C., Boffa, G., Bommarito, G., Petracca, M., Sbragia, E., Novi, G., Lapucci, C., Capello, E., Uccelli, A., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000596 · Cited by 45
Self-citationComparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Swallow, E., Patterson‐Lomba, O., Yin, L., Mehta, R. K., Pelletier, C. L., Kao, D., Sheffield, J. K., Stonehouse, T., & Signorovitch, J. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0169 · Cited by 45
Strategies for Neuroprotection in Multiple Sclerosis and the Role of Calcium
Enders, M., Heider, T., Ludwig, A., & Küerten, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051663 · Cited by 45
The Role of Antibodies in the Pathogenesis of Multiple Sclerosis
Yu, X., Graner, M. W., Kennedy, P. G. E., & Liu, Y. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.533388 · Cited by 45
Zhang, Y., Caldito, N. G., Shirani, A., Salter, A. R., Cutter, G., Culpepper, W. J., Wallin, M. T., Kosa, P. F., Bielekova, B., LUBLIN, F. D., et al. (2020) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420969016 · Cited by 45
Self-citationPatients with multiple sclerosis: a burden and cost of illness study
Battaglia, M. A., Bezzini, D., Cecchini, I., Cordioli, C., Fiorentino, F., Manacorda, T., Nica, M., Ponzio, M., Ritrovato, D., Vassallo, C., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11169-w · Cited by 45
Multiple Sclerosis and Autoimmunity: A Veiled Relationship
Barkhane, Z., Elmadi, J., Kumar, L. S., Pugalenthi, L. S., Ahmad, M., & Reddy, S. (2022) · Cureus · doi:10.7759/cureus.24294 · Cited by 44
Keersmaecker, A. D., Doninck, E. V., Popescu, V., Willem, L., Cambron, M., Laureys, G., D’haeseleer, M., Bjerke, M., Roelant, E., Lemmerling, M. M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362629 · Cited by 44
McKay, K. A., Tremlett, H. L., Zhu, F., Kastrukoff, L. F., Marrie, R. A., & Kingwell, E. (2016) · European Journal of Neurology · doi:10.1111/ene.12990 · Cited by 44
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Signori, A., Izquierdo, G., Lugaresi, A., Hupperts, R., Grand’Maison, F., Sola, P., Horáková, D., Havrdová, E., Prat, A., Girard, M., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517703800 · Cited by 44
Self-citationWhose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals
Col, N. F., Solomon, A. J., Springmann, V., Garbin, C. P., Ionete, C., Pbert, L. A., Álvarez, E., Tierman, B., Hopson, A., Kutz, C. F., et al. (2017) · Medical Decision Making · doi:10.1177/0272989x17724434 · Cited by 44
A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis
Hamidi, V., Couto, E., Ringerike, T., & Klemp, M. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3168w · Cited by 44
BDNF and Tau as Biomarkers of Severity in Multiple Sclerosis
Islas‐Hernández, A., Aguilar-Talamantes, H., Bertado-Cortés, B., Mejia-delCastillo, G. D. J., Carrera-Pineda, R., Cuevas-García, C., & Torre, P. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0374 · Cited by 44
Mechanisms of sex hormones in autoimmunity: focus on EAE
Lasrado, N., Jia, T., Massilamany, C., Franco, R., Illés, Z., & Reddy, J. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00325-4 · Cited by 49
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Coles, A. J., Arnold, D. L., Bass, A. D.-D., Boster, A. L., Compston, D. A. S., Fernández, Ó., Havrdová, E., Nakamura, K., Traboulsee, A. L., Ziemssen, T., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286420982134 · Cited by 44
Escalation vs. Early Intense Therapy in Multiple Sclerosis
Casanova, B., Quintanilla‐Bordás, C., & Gascón, F. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010119 · Cited by 46
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
COHAN, S. L., Benedict, R. H. B., Cree, B., DeLuca, J., Hua, L. H., & Chun, J. J. M. (2022) · CNS Drugs · doi:10.1007/s40263-022-00927-z · Cited by 46
Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042320 · Cited by 46
Autonomic dysfunction in multiple sclerosis: Implications for exercise
Huang, M. R., Jay, O., & Davis, S. L. (2014) · Autonomic Neuroscience · doi:10.1016/j.autneu.2014.10.017 · Cited by 43
Interventions for preventing falls in people with multiple sclerosis
Hayes, S., Kennedy, C. M., Galvin, R., Finlayson, M. L., McGuigan, C., Walsh, C., & Coote, S. B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012475 · Cited by 43
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
